A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification.

Van Cutsem, E; Bang, Y-J; Mansoor, W; Petty, R D; Chao, Y; Cunningham, D; Ferry, D R; Smith, N R; Frewer, P; Ratnayake, J; Stockman, P K; Kilgour, E; Landers, D

Van Cutsem, E; Bang, Y-J; Mansoor, W; Petty, R D; Chao, Y; Cunningham, D; Ferry, D R; Smith, N R; Frewer, P; Ratnayake, J; Stockman, P K; Kilgour, E; Landers, D.

Afiliação

Van Cutsem E; Unit of Digestive Oncology, University Hospitals Leuven and KU Leuven, Leuven, Belgium.
Bang YJ; Biomedical Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Mansoor W; The Christie NHS Foundation Trust, Manchester.
Petty RD; Medical Research Institute, University of Dundee, Dundee.
Chao Y; Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.
Cunningham D; Gastrointestinal and Lymphoma Unit, Royal Marsden Hospital NHS Foundation Trust, Surrey.
Ferry DR; Clinical Oncology, New Cross Hospital, Wolverhampton.
Smith NR; Oncology Innovative Medicines and Early Development, AstraZeneca, Macclesfield.
Frewer P; Oncology Innovative Medicines and Early Development, AstraZeneca, Cambridge, UK.
Ratnayake J; Oncology Innovative Medicines and Early Development, AstraZeneca, Macclesfield.
Stockman PK; Oncology Innovative Medicines and Early Development, AstraZeneca, Macclesfield.
Kilgour E; Oncology Innovative Medicines and Early Development, AstraZeneca, Macclesfield.
Landers D; Oncology Innovative Medicines and Early Development, AstraZeneca, Macclesfield.

Ann Oncol ; 28(6): 1316-1324, 2017 Jun 01.

Article em En | MEDLINE | ID: mdl-29177434

Assuntos

Adenocarcinoma/tratamento farmacológico; Antineoplásicos/administração & dosagem; Benzamidas/administração & dosagem; Paclitaxel/administração & dosagem; Piperazinas/administração & dosagem; Pirazóis/administração & dosagem; Receptor Tipo 2 de Fator de Crescimento de Fibroblastos/genética; Neoplasias Gástricas/tratamento farmacológico; Adenocarcinoma/genética; Antineoplásicos/efeitos adversos; Benzamidas/efeitos adversos; Linhagem Celular Tumoral; Intervalo Livre de Doença; Amplificação de Genes; Humanos; Paclitaxel/efeitos adversos; Piperazinas/efeitos adversos; Pirazóis/efeitos adversos; Neoplasias Gástricas/genética

Palavras-chave

AZD4547; clinical efficacy; fibroblast growth factor receptor; fluorescence in situ hybridization; gastric cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piperazinas / Pirazóis / Neoplasias Gástricas / Benzamidas / Adenocarcinoma / Paclitaxel / Receptor Tipo 2 de Fator de Crescimento de Fibroblastos / Antineoplásicos Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google